Vimarsana
Biggest News Aggregation in the World

Page 4 - Patrick Burnett News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Burnett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Burnett Today - Breaking & Trending Today

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript - Vimarsana News

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript November 3, 2023 Arcutis Biotherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.9. Operator: Good day, and welcome to the Arcutis Biotherapeutics Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like […]

Source: yahoo.com
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children ... | Region - Vimarsana News

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children ... | Region

WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S.

FDA Expands Indication for Non-Steroid Cream to Treat Psoriasis In Children as Young as 6 Years of Age - Vimarsana News

FDA Expands Indication for Non-Steroid Cream to Treat Psoriasis In Children as Young as 6 Years of Age

Roflumilast is the first topical agent indicated to treat psoriasis in sensitive intertriginous areas of the skin.

Zoryve Cream Approved for Pediatric Patients With Psoriasis - Vimarsana News

Zoryve Cream Approved for Pediatric Patients With Psoriasis

The FDA has approved Zoryve (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis in children ages 6 to 11 years.

Source: empr.com
Phase 3 Trial Reinforces Favorability of Roflumilast Cream 0.05% for Atopic Dermatitis in Children - Vimarsana News

Phase 3 Trial Reinforces Favorability of Roflumilast Cream 0.05% for Atopic Dermatitis in Children

A supplemental New Drug Application will be submitted for roflumilast cream 0.05% for the treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.